Ignite Creation Date:
2024-05-05 @ 4:54 PM
Last Modification Date:
2024-10-26 @ 9:25 AM
Study NCT ID:
NCT00345761
Status:
COMPLETED
Last Update Posted:
2010-08-16
First Post:
2006-06-27
Brief Title:
Clinical Study of Capecitabine Oxaliplatin and Bevacizumab in Colorectal Cancer
Sponsor:
Chugai Pharmaceutical
Organization:
Chugai Pharmaceutical
Study Overview
Official Title:
Phase III Study of R340 Capecitabine L-OHP Oxaliplatin and R435 Bevacizumab in Advanced andor Metastatic Colorectal Cancer
Status:
COMPLETED
Status Verified Date:
2010-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will evaluate the efficacy safety and pharmacokinetics of capecitabine 2000 mgm2day by mouth po day 1 pm-day 15 am every 3 weeks q3w oxaliplatin 130 mgm2 intravenously iv day 1 q3w and bevacizumab 75 mgkg iv day 1 q3w in patients with advanced andor metastatic colorectal cancer
Detailed Description:
This study will evaluate the efficacy safety and pharmacokinetics of Capecitabine 2000 mgm2day po day 1 pm-day 15 am q3w Oxaliplatin 130 mgm2 iv day 1 q3w and Bevacizumab 75 mgkg iv day 1 q3w in patients with advanced andor metastatic colorectal cancer
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None